SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Reports of CEO Jensen Huangs relationship with a person suspected by U.S. officials of ties to Chinese intelligence, and Nvidias board investigation, are driving attention. Traders are divided over whether this is mainly personal-headline risk or a more serious threat involving company secrets, export scrutiny, and Huangs leadership, with some viewing the selloff as a buying opportunity.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Attention centers on ANKTIVA plus BCG meeting the primary endpoint in the BCG-naive bladder cancer trial, with traders awaiting full results and a possible label-expansion filing. Bullish hopes for a larger market and a short squeeze are tempered by caution over the undisclosed details, volatile trading, and uncertainty about quarterly revenue.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics quarterly results and raised full-year outlook have focused attention on Briumvis commercial growth, with bullish traders pointing to the drugs momentum. The community is also watching for the upcoming subcutaneous Briumvi trial readout, while buyout and short-squeeze speculation competes with concerns that earnings expectations are already priced in.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

BitMines sharp share-price weakness and underperformance versus ether are driving discussion, with traders linking the pressure to the crypto selloff and questioning whether its ETH treasury and buybacks can support the stock while ether is weak. Bulls see the discount to net asset value and progress toward the companys ETH-ownership goal as attractive, while bears argue buybacks cannot offset falling crypto values and criticize managements strategy.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.11892236 USD and is down -3.62 over the last 24 hours. It is currently trading on 1894 active market(s) with $1,884,610,999.15 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRPs steep decline alongside a broader crypto sell-off has traders focused on whether it will hold around the $1 level, with some expecting further losses and others buying or averaging down. Political and regulatory uncertaintyincluding debate over the Clarity Actis cited by some as a headwind, while others argue the weakness reflects the wider market or XRPs own lack of price response to favorable news.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedixs agreement to acquire substantially all of Heron Therapeutics assets is driving discussion, with traders weighing the portfolio expansion against concerns about the cash outlay, newly issued shares and managements capital-allocation priorities. Some view the deal as a non-dilutive-financing-supported growth move, while others are skeptical about its value and the stocks prospects around earnings.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Traders are discussing a potential rotation into AMD amid Nvidia CEO-related governance headlines, while debating whether AMD can gain from customers seeking alternatives or whether sector-wide AI concerns will weigh on both stocks. Bullish sentiment is also supported by AMDs strong quarterly results and an Oppenheimer upgrade, though some traders view the sharp rebound as potentially temporary.

Constellation Energy Corp. engages in the generation, supply, and marketing of clean electricity, and renewable energy products and solutions. The firm also offers wholesale energy, retail products and services. It operates under the following geographical segments: Mid-Atlantic, Midwest, New York, Electric Reliability Council of Texas (ERCOT), and Other Power Regions Segment. The company was founded in 1960 and is headquartered in Baltimore, MD.

Constellation Energy Corporation

Stronger-than-expected Q3 results and a raised full-year profit outlook are driving the latest rally. Traders are broadly upbeat, though some remain focused on the outlook and concerns about capital spending and debt.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,200,877.25744775. The last known price of Ethereum is 2,141.49627095 USD and is down -4.09 over the last 24 hours. It is currently trading on 14297 active market(s) with $9,084,277,576.13 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereums sharp slide alongside a broader crypto selloff is driving attention, with traders citing heavy selling, liquidations and weak price action while debating whether macro and tech-market pressure are contributing. Bearish posts warn of further downside, while others view the decline as a buying opportunity; no single cause is established.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

Zura Bios Phase 2 hidradenitis suppurativa study missing its primary endpoint is being viewed by some traders as a favorable competitive read-through for MoonLakes sonelokimab, though the studies are not direct comparisons. Discussion also points to a recent analyst upgrade and the upcoming FDA decision on whether to accept MoonLakes BLA for review.

statis crypto Watchlist

Bitcoin

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$PFE spent $3.02 billion on research and development, the money it puts into developing new drugs, in July to September 2026. That is up 18.5% from $2.55 billion a year earlier, while revenue was flat at $16.58 billion. 
 
Is it growing, does it make money, can it pay its bills? The Techdamentals IV Calculator reads the fundamentals in plain English, from the company&#39;s own reported numbers. See the fundamentals for yourself and sign up for free. 
 
Educational, not advice. 
 
https://techdamentals.com/v3/PFE?ref=st

Not a guru's take. Pfizer Inc.'s own reported numbers, read for you in plain English: is it growing, does it make money, does it bring in cash, can it pay its bills, what you pay for it. Free, no card. Educational, not advice.

Techdamentals

What PFE's fundamentals actually say

StockTwits Web

Pfizer Inc

 spent $3.02 billion on research and development, the money it puts into developing new drugs, in July to September 2026. That is up 18.5% from $2.55 billion a year earlier, while revenue was flat at $16.58 billion. 
 
Is it growing, does it make money, can it pay its bills? The Techdamentals IV Calculator reads the fundamentals in plain English, from the company's own reported numbers. See the fundamentals for yourself and sign up for free. 
 
Educational, not advice. 
 


yeah that 18% jump is the tell imo. $PFE is pouring it into the obesity pipeline, 10 phase 3 trials running and berobenatide aiming at a first approval in 2028. acquired products already up 32% this quarter, the spend is chasing the next wave

 is pouring it into the obesity pipeline, 10 phase 3 trials running and berobenatide aiming at a first approval in 2028. acquired products already up 32% this quarter, the spend is chasing the next wave